Q1’FY25 Earnings Call Supplemental Presentation November 6, 2024
Forward-looking Statements This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. 2 Proprietary and Confidential Property of Accuray Safe Harbor Statement Statements in this presentation (including the oral commentary that accompanies it) that are not statements of historical fact are forward-looking statements and are subject to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this presentation relate, but are not limited, to: expectations regarding adjusted EBITDA and revenue; our ability to deliver on our goals and strategic growth plans; our expectations related to the markets and regions in which we operate; expectations related to our China joint venture, including related to the Tomo-C System and margin deferral from the China joint venture; expectations regarding environmental, social and governance initiatives at the Company; and expectations related to new product innovations and offerings as well as revenue growth and market share going forward. Forward-looking statements generally can be identified by words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “projects,” “may,” “will be,” “will continue,” and similar expressions. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations. These risks and uncertainties include, but are not limited to: risks related to the effect of the global macroeconomic environment on the operations of the company and those of its customers and suppliers; disruptions to our supply chain, including increased logistics costs; the company's ability to achieve widespread market acceptance of its products; the company’s ability to realize the expected benefits of the China joint venture and other partnerships; risks inherent in international operations; the company's ability to maintain or increase its gross margins on product sales and services; delays in regulatory approvals or the development or release of new offerings; the company's ability to meet the covenants under its credit facilities; the company's ability to convert backlog to revenue and other risks identified under the heading “Risk Factors” in our annual report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on September 19, 2024, and as updated periodically with our other filings with the SEC. Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. Accuray assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements. Non-GAAP Financial Measures This presentation also contains non-GAAP financial measures. Management believes that non-GAAP financial measures provide useful supplemental information to management and investors regarding the performance of the company and facilitates a more meaningful comparison of results for current periods with previous operating results. Additionally, these non-GAAP financial measures assist management in analyzing future trends, making strategic and business decisions, and establishing internal budgets and forecasts. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP measure is provided in the Appendix. Accuray has also reported certain operating results on a constant currency basis in order to facilitate period-to-period comparisons of its results without regard to the impact of foreign currency exchange rate fluctuations. Management believes disclosure of non-GAAP constant currency results is helpful to investors because it facilitates period-to-period comparisons of the company's results by increasing the transparency of the underlying performance by excluding the impact of foreign currency exchange rate fluctuations. Accuray calculates the constant currency amounts by translating local currency amounts in the current period using the same foreign translation rate used in the prior period being compared against rather than the actual exchange rate in effect during the current period. There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the company’s consolidated financial statements prepared in accordance with GAAP. Medical Advice Disclaimer Accuray Incorporated as a medical device manufacturer cannot and does not recommend specific treatment approaches. Individual results may vary.
Highlights Strong China performance with significant interest in the Tomo® C System Service contract recurring revenue growth of 5% YOY, outpacing installed base growth Raising full year fiscal 2025 guidance Clinical data published in NEJM support the use of SBRT for the treatment of prostate cancer
Vision To expand the curative power of radiation therapy to improve as many lives as possible Mission To think, act, and execute beyond expectations every day to deliver better, safer radiation therapy solutions and help patients get back to living their lives, faster
Customer and Patient Focused Priorities Advance Care by providing solutions that address the biggest pain points in RT Drive Patient Access to radiotherapy treatments in developed and high potential underserved markets Delight Customers by ensuring high operational performance so no patient is rescheduled Hope Confidence Conquer Cancer by Closing the Gaps to Care
PACE-B Prostate Study Published in NEJM Study shows stereotactic body radiation therapy (SBRT) provides comparable results to conventional radiotherapy in 75% less time1 ~ 1 in 8 men in the U.S. will be diagnosed with prostate cancer2 Trial compared 5-fraction SBRT to conventional radiotherapy (CRT)1 41% of men receiving SBRT were treated using the CyberKnife® System1 At 5 years, SBRT and CRT provided similar rates of cancer control, tolerability and sexual functioning1 SBRT significantly reduces the time men must spend undergoing care 1. van As N, Griffin C, Tree A, et al. Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer. N Engl J Med. 2024 Oct 17;391(15):1413-1425. doi:10.1056/NEJMoa2403365 2. American Cancer Society 3. Accuray and The Royal Marsden press releases issued October 17, 2024 “We expect our trial to be practice changing . . .” Chief Investigator Professor Nicholas van As3
The CyberKnife® System: First and Only Robotic Radiotherapy Platform CyberKnife® Platform Dedicated SRS/SBRT System First frameless SRS system First SRS/SBRT system to track and automatically adjust for motion in real time Unmatched sub-millimeter robotic accuracy w/o restrictive devices All Markets
The Radixact® System: Only System Specifically Designed for Integrated 3D Daily IG-IMRT TomoTherapy®/Radixact® Platform First to allow for continuous helical treatment delivery First to offer ring gantry platform First to integrate daily CT imaging into the treatment process First to offer large one meter+ treatment field with dose painting All Markets
Expanding Access to Global Value Segment Accuray Helix™ Tomo® C Locally Manufactured, China Solution Manufactured in Madison, Wisconsin Fueling Growth in China Type B Market Designed for Workflow Efficiency $600M Annual TAM* $300M Annual TAM India/LATAM* *DIRAC database and proprietary data
China Business Progress Proprietary and Confidential Property of Accuray Q1 FY25 milestone of systems built at the Tianjin facility Ended FY24 with Tomo C System NMPA license, introduction and ramp up 30% YOY revenue growth driven by both Type A and B markets Radiotherapy market share leader with CyberKnife® and Radixact® Systems 22% growth in new installed base customers YOY Above market new order growth
China Margin Impact – Tomo® C System Reported revenue remains the same, with or without China deferral Due to JV accounting rules, 49% of total margin needs to be deferred upon shipment to the JV Margin is released when the JV ships the system to the customer Deferred margin is reflected on the Balance Sheet, together with other items, under Assets as “Investment in JV” Expect approximately $3 - $4M of net release included in revised guidance 1 Adjusted EBITDA is a non-GAAP measure. Please see Slide 17 and 19 for a reconciliation of Adjusted EBITDA to the most directly comparable GAAP measure. 2 Gross Margin % (Excl China Margin Impact) is a non-GAAP measure. Please see Slides 20 and 21 for a reconciliation of Gross Margin % (Excl China Margin Impact) to the most directly comparable GAAP measure. 1 1 1 1 2
Q1’FY25 Financials Revenues $101.5 (2%) Product $48.4 (9%) Service $53.2 5% Gross Margin 33.9% (4.1%) Op. Expenses $36.6 (2%) Adj. EBITDA 1 $3.1 (52%) KEY FINANCIAL METRICS $M Q1 Y/Y Highlights Strong revenue performance in China with Tomo® C Systems and growth in service business Growth in service contract revenue exceeding install base Excluding Tomo-C margin impact, gross margin would have been 35.9% 2% annual decrease in OPEX driven by cost control Trailing 12-month Book to Bill ratio of 1.5 1. Adjusted EBITDA is a non-GAAP measure. Please see Slide 17 for a reconciliation of Adjusted EBITDA to the most directly comparable GAAP measure. 2. Percentages shown on a constant currency basis to facilitate period-to-period comparisons without regard to the impact of foreign currency exchange rate fluctuations. Y/Y XFX2 (2%) (9%) 6%
FY25 Revised Guidance Revenue Adjusted EBITDA1 Previous Guidance Range $27.5M - $29.5M +40% - 50% 1 Adjusted EBITDA is a non-GAAP measure. Please see Slide 18 for a reconciliation of Adjusted EBITDA to the most directly comparable GAAP measure. $ in millions % = YoY Growth $460M - $470M +3% - 5% Revised Guidance Range $28M - $30M +42% - 52% $462M - $472M +3.5% - 6%
FY2025 Fiscal Focused Priorities Outpace the Market and Grow Customer Base Expand Service and Solutions Recurring Revenue Improve Profitability and Operational Excellence Strengthen Balance Sheet and Cash Flow
ESG at Accuray Reduce cost of treatment through value-based care Expand access in low-income communities and developing countries with Accuray Helix™ and Tomo® C Systems Expanding Access to Healthcare Consistently support local charities (i.e., Habitat for Humanity; Family Giving Tree) Committed to supporting policies covering fair-trade, fair-wage and other labor policies throughout our global footprint Building Strong Communities Building a Culture of Inclusion and Diversity Established internal DEI Committee Formed partnerships with diversity job boards to engage underrepresented minority groups Enhanced internal DEI trainings Regular celebration of diversity (i.e., Pride) Enhancing Environmental Stability Remanufacture and recertify >100 types of equipment and static materials for reuse Recycling programs in all global offices EV stalls available in key office locations Expect to build ability to measure greenhouse gas emissions generated by the Company
Thank you
$K GAAP net income (loss) Stock-based compensation Interest expense, net Provision for income taxes Adjusted EBITDA Depreciation and amortization Three Months Ended September 30, Three Months Ended September 30, 2023 2024 $ $ $ $ (3,954) 1,464 2,354 2,652 625 3,141 (2,969) 1,251 2,392 2,628 1,932 6,504 ERP and ERP related expenditures 0 1,270 GAAP to Adjusted EBITDA Q1 FY’25 and Q1 FY’24 Reconciliation of Net Income (Loss) to Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization and Stock-Based Compensation (Adjusted EBITDA)
$K GAAP net income (loss) Stock-based compensation Interest expense, net Provision for income taxes Adjusted EBITDA Depreciation and amortization To From $ $ $ $ (4,500) 6,500 10,000 13,000 3,000 28,000 (2,500) 6,500 10,000 13,000 3,000 30,000 GAAP to Adjusted EBITDA FY’25 – Forward Looking Guidance Reconciliation of Net Income (Loss) to Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization and Stock-Based Compensation (Adjusted EBITDA) Twelve Months Ended June 30, 2025
$K GAAP net income (loss) Stock-based compensation Interest expense, net Restructuring charges Depreciation and amortization Twelve Months Ended June 30, Twelve Months Ended June 30, 2023 2024 $ $ (15,545) 5,905 9,483 10,676 2,633 3,725 (9,280) 4,527 10,053 10,340 2,738 2,492 ERP and ERP related expenditures 2,815 3,078 GAAP to Adjusted EBITDA FY2024 and FY2023 Reconciliation of Net Income (Loss) to Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization and Stock-Based Compensation (Adjusted EBITDA) Adjusted EBITDA $ $ 19,692 23,948 Provision for income taxes
$K Total Net Revenue Gross Profit TT-C China Margin Deferral Gross Margin % excl TT-C China Margin Impact Total Cost of Revenue Twelve Months Ended June 30, Twelve Months Ended June 30, 2023 2024 $ $ 446,551 (303,630) 142,921 (3,031) 32.68% 447,605 (293,645) 153,960 (1,216) 34.67% Gross Profit excl TT-C China Margin Impact 145,952 155,176 Gross Margin to Gross Margin Excluding China Margin Impact Reconciliation of Gross margin to Gross margin excluding China Margin Impact $ $
$K Total Net Revenue Gross Profit TT-C China Margin Deferral Gross Margin % excl TT-C China Margin Impact Total Cost of Revenue Three Months Ended September 30, 2024 $ 101,545 (67,076) 34,469 (1,993) 35.91% Gross Profit excl TT-C China Margin Impact 36,462 Gross Margin to Gross Margin Excluding China Margin Impact Reconciliation of Gross margin to Gross margin excluding China Margin Impact $
